Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine.
Fontana D, Mauri M, Renso R, Docci M, Crespiatico I, Røst LM, Jang M, Niro A, D'Aliberti D, Massimino L, Bertagna M, Zambrotta G, Bossi M, Citterio S, Crescenzi B, Fanelli F, Cassina V, Corti R, Salerno D, Nardo L, Chinello C, Mantegazza F, Mecucci C, Magni F, Cavaletti G, Bruheim P, Rea D, Larsen S, Gambacorti-Passerini C, Piazza R. Fontana D, et al. Among authors: renso r. Nat Commun. 2020 Nov 23;11(1):5938. doi: 10.1038/s41467-020-19721-w. Nat Commun. 2020. PMID: 33230096 Free PMC article.
Being a Myeloproliferative Patient in COVID-19 Era: The Mytico Study.
Cavalca F, Renso R, Zambrotta GPM, Gambacorti-Passerini C, Elli EM. Cavalca F, et al. Among authors: renso r. Front Oncol. 2021 Apr 15;11:668261. doi: 10.3389/fonc.2021.668261. eCollection 2021. Front Oncol. 2021. PMID: 33937081 Free PMC article.
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy.
Bossi E, Aroldi A, Brioschi FA, Steidl C, Baretta S, Renso R, Verga L, Fontana D, Sharma GG, Mologni L, Mussolin L, Piazza R, Gambacorti-Passerini C. Bossi E, et al. Among authors: renso r. Am J Hematol. 2020 Dec;95(12):E319-E321. doi: 10.1002/ajh.25967. Epub 2020 Sep 3. Am J Hematol. 2020. PMID: 32808682 Free article. Clinical Trial. No abstract available.
Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients.
Maffioli M, Giorgino T, Mora B, Iurlo A, Elli E, Finazzi MC, Caramella M, Rumi E, Carraro MC, Polverelli N, D'Adda M, Malato S, Rossi M, Molteni A, Vismara A, Sissa C, Spina F, Anghilieri M, Cattaneo D, Renso R, Bellini M, Pioltelli ML, Cavalloni C, Barraco D, Accetta R, Bertù L, Della Porta MG, Passamonti F. Maffioli M, et al. Among authors: renso r. Blood Adv. 2019 Nov 12;3(21):3196-3200. doi: 10.1182/bloodadvances.2019000646. Blood Adv. 2019. PMID: 31698448 Free PMC article.
Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL study.
Elli EM, Di Veroli A, Bartoletti D, Iurlo A, Carmosino I, Benevolo G, Abruzzese E, Bonifacio M, Bergamaschi M, Polverelli N, Caramella M, Cilloni D, Tiribelli M, Pugliese N, Caocci G, Crisà E, Porrini R, Markovic U, Renso R, Auteri G, Cattaneo D, Trawinska MM, Scaffidi L, Biale L, Bucelli C, Breccia M, Gambacorti-Passerini C, Palumbo GA, Latagliata R, Palandri F. Elli EM, et al. Among authors: renso r. Br J Haematol. 2022 Apr;197(2):190-200. doi: 10.1111/bjh.18057. Epub 2022 Feb 8. Br J Haematol. 2022. PMID: 35137397 Free article.
Non transferrin bound iron (NTBI) in acute leukemias throughout conventional intensive chemotherapy: kinetics of its appearance and potential predictive role in infectious complications.
Belotti A, Duca L, Borin L, Realini S, Renso R, Parma M, Pioltelli P, Pogliani E, Cappellini MD. Belotti A, et al. Among authors: renso r. Leuk Res. 2015 Jan;39(1):88-91. doi: 10.1016/j.leukres.2014.11.003. Epub 2014 Nov 15. Leuk Res. 2015. PMID: 25435028 Clinical Trial.